Buy or sell CRISPR Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

CRISPR Therapeutics Stock

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

About CRISPR Therapeutics Stock

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Funding History

April 2014$25.0M
April 2015$64.0M
June 2016$38.0M

Management

Scientific Founders

Daniel Anderson

Scientific Founders

Emmanuelle Charpentier

Founder & CFO

Shaun Foy

Founder & Chief Executive Officer

Rodger Novak

Scientific Founders

Craig Mello

Chief Scientific Officer

Bill Lundberg

Scientific Founders

Chad Cowan

Scientific Founders

Matthew Porteus

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from CRISPR Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 140K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo